Compare Gitlab Inc (GTLB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Recursion Pharmaceuticals Inc — how do they compare? Gitlab Inc trades at $54.78 (market cap $8.92B), while Recursion Pharmaceuticals Inc trades at $4.26 (market cap $2.14B). The key difference: Gitlab Inc is far larger — about 4.2× Recursion Pharmaceuticals Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GTLB | RXRX | |
|---|---|---|
Market Cap | $8.92B | $2.14B |
Volume | 4,716,893 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $53.56 | $6.79 |
52-Week Low | $19.42 | $2.84 |
Typical Hold Time | 62 Days | 22 Days |
Enterprise Value | $7.66B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) is trading at $54.74, up 5.29% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings expectations in recent quarters. Revenue growth remains robust at 21.3% year-over-year in Q2 2026, though the company continues to operate at a net loss. Recent news highlights strong AI-driven demand and improved sales momentum, with the company raising its full-year guidance.
The outlook is cautiously optimistic with significant revenue growth potential from AI integration, but high valuation multiples and persistent profitability challenges present risks. Analyst consensus leans neutral with a $49.71 price target below current levels, suggesting limited near-term upside despite positive business developments.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
